Dementia

Eisai has accumulated extensive experience and achievements in the field of dementia over 40 years. We launched ARICEPT® in 1997, which has since received regulatory approval in more than 100 countries. Since 2023, we have provided LEQEMBI®, an anti-amyloid-β protofibril antibody that targets the underlying cause of Alzheimer’s disease.

As well as amyloid-β, Eisai is targeting tau pathology, another characteristic of AD neuropathology, through the clinical development of the anti-microtubule binding region (MTBR) tau antibody E2814. We are also developing E2511 and E2025, which are reactivating dysfunctional neurons by dementia. Furthermore, recognizing that addressing complex pathology is essential to overcome dementia, we are also developing of disease-modifying treatments targeting other pathologies such as α-synuclein, which are causative factors in other forms of dementia, in anticipation of addressing neurodegenerative diseases beyond Alzheimer's disease. These research and development efforts pushed forward not only by Eisai’s accumulated experience, knowledge, and expertise in dementia drug development, but also through collaboration with research institutions and other organizations with expertise in the disease and access to cutting-edge scientific insights and data.

In addition to therapeutic approaches, Eisai is working to build a dementia ecosystem through the development of digital solutions and collaboration with other industries, academia, and local governments. This initiative aims to provide comprehensive support for dementia patients, from prevention to care. Among these efforts, initiatives include the development of digital solutions by the digital business company Theoria Technologies, the creation of health service platforms in collaboration with other companies, and joint efforts with academia and diagnostic drug developers to establish and promote blood-based diagnostics that detect amyloid-β pathology in the brain for the earliest possible diagnosis of Alzheimer’s disease. Additional efforts include supporting dementia screening in partnership with local governments and forming business alliances with insurance companies to help reduce the medical and caregiving burden on people living with dementia.

Please see here for our history of research and development in the dementia field.

Eisai has established long-term objectives and KPIs for fiscal 2030 and we are managing our progress towards the realization of a society where everyone can overcome dementia, through the creation of a dementia ecosystem that supports people through all stages of life, from healthy to high-risk state, through onset and treatment of disease, to follow-up/prognosis.

Please see here for long-term objectives, KPIs and risks in the dementia area.

Please see here for our medium-term business plan “EWAY Future & Beyond” and its progress.

Please see here for an overview of our latest major R&D pipeline for dementia.

With our vision of supporting patients and the people to realize their fullest lives, we are creating solutions based on science and data in the area of dementia, where we have the greatest strength, and establishing an ecosystem in collaboration with other industries.

Based on our long-standing hhc (human health care) concept, we will further enhance our hhc process of understanding the anxieties of patients and formulating strategies to resolve those anxieties, keeping ourselves close to the lives of the people.

As a result of such efforts, we will aim to evolve into an “hhceco” (hhc+ ecosystem) Company that will support and enable the people to realize their fullest life from when they are in good health until their final moments.

Please see here for an overview of our collaboration with other industries and local municipalities.

Please see here for an overview of our collaborations with partners on blood biomarkers.

To help more people in the daily living domain understand Eisai’s commitment and efforts in pursuing “new answers” to dementia, we have launched a dedicated website.

For more information about “New Answers to Dementia”, please see here. (Japanese only)